Johnson & Johnson (JNJ) Shares Sold by First Merchants Corp

First Merchants Corp decreased its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.2% during the second quarter, HoldingsChannel.com reports. The firm owned 51,924 shares of the company’s stock after selling 2,290 shares during the quarter. Johnson & Johnson comprises about 1.1% of First Merchants Corp’s holdings, making the stock its 20th biggest position. First Merchants Corp’s holdings in Johnson & Johnson were worth $6,301,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors also recently modified their holdings of JNJ. BlackRock Inc. lifted its position in Johnson & Johnson by 4.7% during the first quarter. BlackRock Inc. now owns 175,389,024 shares of the company’s stock valued at $22,476,102,000 after purchasing an additional 7,853,141 shares during the period. Boston Partners lifted its position in Johnson & Johnson by 68.7% during the first quarter. Boston Partners now owns 12,783,909 shares of the company’s stock valued at $1,638,258,000 after purchasing an additional 5,207,124 shares during the period. Cornerstone Wealth Management LLC lifted its position in Johnson & Johnson by 10,307.6% during the second quarter. Cornerstone Wealth Management LLC now owns 2,497,098 shares of the company’s stock valued at $20,537,000 after purchasing an additional 2,473,105 shares during the period. Bank of Montreal Can lifted its position in Johnson & Johnson by 36.1% during the second quarter. Bank of Montreal Can now owns 6,910,459 shares of the company’s stock valued at $838,515,000 after purchasing an additional 1,833,622 shares during the period. Finally, Summit Trail Advisors LLC increased its holdings in Johnson & Johnson by 11,692.6% during the first quarter. Summit Trail Advisors LLC now owns 1,767,832 shares of the company’s stock valued at $1,768,000 after buying an additional 1,752,841 shares during the last quarter. Institutional investors own 66.68% of the company’s stock.

Shares of JNJ stock opened at $136.97 on Friday. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.65 and a quick ratio of 1.33. The company has a market cap of $372.06 billion, a price-to-earnings ratio of 18.76, a price-to-earnings-growth ratio of 2.17 and a beta of 0.70. Johnson & Johnson has a 12 month low of $118.62 and a 12 month high of $148.32.



Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, October 16th. The company reported $2.05 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $2.03 by $0.02. The firm had revenue of $20.35 billion during the quarter, compared to analysts’ expectations of $20.05 billion. Johnson & Johnson had a net margin of 1.89% and a return on equity of 34.97%. The company’s revenue for the quarter was up 3.6% compared to the same quarter last year. During the same period in the prior year, the company posted $1.90 earnings per share. As a group, research analysts predict that Johnson & Johnson will post 8.16 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 11th. Stockholders of record on Tuesday, November 27th will be paid a $0.90 dividend. The ex-dividend date of this dividend is Monday, November 26th. This represents a $3.60 dividend on an annualized basis and a dividend yield of 2.63%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 49.32%.

A number of analysts have commented on the stock. Credit Suisse Group set a $149.00 target price on shares of Johnson & Johnson and gave the company a “buy” rating in a report on Sunday, October 14th. HC Wainwright reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Wednesday, October 17th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $160.00 target price (up from $155.00) on shares of Johnson & Johnson in a report on Wednesday, October 17th. Raymond James upped their target price on shares of Johnson & Johnson from $144.00 to $149.00 and gave the company an “outperform” rating in a report on Wednesday, October 17th. Finally, Citigroup upped their target price on shares of Johnson & Johnson from $137.00 to $148.00 and gave the company a “neutral” rating in a report on Monday, October 22nd. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have issued a buy rating to the company’s stock. Johnson & Johnson currently has a consensus rating of “Hold” and a consensus target price of $142.54.

In other news, COO Michael E. Sneed sold 29,000 shares of the stock in a transaction on Monday, August 27th. The shares were sold at an average price of $134.80, for a total value of $3,909,200.00. Following the completion of the sale, the chief operating officer now directly owns 59,124 shares of the company’s stock, valued at $7,969,915.20. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CAO Ronald A. Kapusta sold 7,899 shares of the stock in a transaction on Friday, September 7th. The stock was sold at an average price of $137.18, for a total transaction of $1,083,584.82. Following the completion of the sale, the chief accounting officer now directly owns 25,725 shares of the company’s stock, valued at $3,528,955.50. The disclosure for this sale can be found here. Corporate insiders own 0.22% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. Its Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, RoC, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.

Further Reading: Market Capitalization in the Stock Market

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply